Canada peptide regulation

Canada regulates peptides under the Food and Drugs Act (FDA, R.S.C. 1985, c. F-27) and Food and Drug Regulations (C.R.C., c. 870). Peptides are classified as drugs, natural health products (NHPs), or food ingredients based on composition, intended use, and claims. Most bioactive "research peptides" sold online are unauthorised drugs without a legal market pathway.

• Health Canada: Therapeutic Products Directorate (TPD) — review; Regulatory Operations and Enforcement Branch (ROEB) — compliance and enforcement.

• CBSA (Canada Border Services Agency): screens imports at ports of entry.

• Provincial pharmacy regulatory authorities (e.g., OCP, OPQ, ACP, BC College of Pharmacists): enforce compounding standards.

• NAPRA: develops model standards for pharmacy compounding.

Key instruments:

• Food and Drugs Act (R.S.C., 1985, c. F-27).

• Food and Drug Regulations (C.R.C., c. 870) — Part C (drugs).

• Natural Health Products Regulations (SOR/2003-196).

• Controlled Drugs and Substances Act (S.C., 1996, c. 19).

Approved peptide drugs (with Drug Identification Numbers) include insulin and analogues, GLP-1 receptor agonists (semaglutide/Ozempic/Wegovy, liraglutide/ Victoza/Saxenda, tirzepatide/Mounjaro), teriparatide (Forteo), leuprolide (Lupron), octreotide (Sandostatin), desmopressin, calcitonin, and bacitracin (topical).

Source: Health Canada Drug Product Database, https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html

Clinical trials require a Clinical Trial Application (CTA) under Part C, Division 5 of the Food and Drug Regulations, plus Research Ethics Board approval. No trial may proceed without Health Canada authorisation.

POL-0051 — Health Canada's Policy on Manufacturing and Compounding Drug Products distinguishes manufacturing (Establishment Licence + GMP) from compounding (exempt from drug approval if prescription-based, patient-specific). Compounding of "essentially a copy" of an approved drug is not compliant.

NAPRA Model Standards for Pharmacy Compounding (sterile, non-hazardous, hazardous). Sterile compounding requires compliance with CSA standard Z314.8. Provincial authorities enforce these standards.

Most peptide raw materials from "research chemical" suppliers do not meet compendial-grade quality expectations for compounding.

• Import: Food and Drug Regulations s. A.01.040 requires that every imported drug be manufactured in a GMP-equivalent facility and the importer hold an Establishment Licence. CBSA screens for unapproved peptides.

• Personal import: Canadian residents generally may not import prescription drugs for personal use by mail or courier, subject to limited exceptions in GUI-0116. Visitors may bring a personal-use quantity under separate conditions. Rules differ for prescription drugs, non-prescription products, controlled substances, carried goods, and mailed shipments; a generic “30–90 day” allowance must not be applied across those categories.

• Sale: FDA s. 8 prohibits sale of unapproved new drugs.

• Advertising: FDA s. 9(1) prohibits false/misleading labelling. FDA s. 3 prohibits advertising therapeutic products for Schedule A diseases (cancer, diabetes, etc.) to the public.

No statutory "research use only" exemption exists in Canada. FDA s. 30.05 grants the Minister exemption power, but it is not routinely used for individual peptide products. "Research use only" labelling is a common carrier defence, not a recognised category. Products implicitly marketed for human use through health claims may constitute unauthorized drug promotion or supply, depending on intended use, claims, product and transaction facts.

WADA Prohibited List is enforced by the Canadian Centre for Ethics in Sport (CCES).

The current consolidated CDSA schedules reviewed for this snapshot do not name GHRP-2, GHRP-6, or ipamorelin. SOR/2026-71 concerned named synthetic opioids, not those peptides; this page therefore makes no controlled-substance claim for them. Any class-based coverage must be established from the current statutory text and case-specific legal analysis rather than inferred from WADA status.

• CBSA routinely seizes shipments of unapproved peptides (BPC-157, TB-500, GHRPs) destined for consumers.

• Health Canada has taken action against clinics promoting peptide therapies.

• Uncertainty: the classification boundary between drug and NHP for short peptide sequences remains untested at scale.

This is general regulatory research, not legal advice. Classification can turn on composition, claims, intended use, route, supplier role, and facts not captured by a product name.

1. Food and Drugs Act (R.S.C., 1985, c. F-27). https://laws-lois.justice.gc.ca/eng/acts/F-27/

2. Food and Drug Regulations (C.R.C., c. 870). https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.,_c._870/

3. Natural Health Products Regulations (SOR/2003-196). https://laws-lois.justice.gc.ca/eng/regulations/SOR-2003-196/

4. POL-0051. https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/guidance-documents/policy-manufacturing-compounding-drug-products.html

5. Drug Product Database. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html

6. Controlled Drugs and Substances Act. https://laws-lois.justice.gc.ca/eng/acts/C-38.8/

7. NAPRA Compounding Standards. https://www.napra.ca